The Effect of JNJ-39393406 on Event Related Potentials in Stable Schizophrenic Patients

Summary

This study in patients with stable schizophrenia will investigate the effect of JNJ-39393406 on Event Related Potentials (Auditory Evoked Potential \[AEP\] P50, AEP P300 and Mismatch Negativity \[MMN\]) after single dose administration.

Timeline

Start

2009-08

Primary completion

—

Completion

2011-03

Outcome

Missed primary endpoint

Stopped (Enrollment): “Efficacy signals were insufficiently strong to justify recruitment of additional patients.”

paper No indication was found that JNJ-39393406 has the potential to reverse basic deficits of information processing in schizophrenia (sensory P50 gating) PMID 22766391 ↗

Publications

• Winterer G, Gallinat J, Brinkmeyer J, Musso F, Kornhuber J, Thuerauf N, Rujescu D, Favis R, Sun Y, Franc MA, Ouwerkerk-Mahadevan S, Janssens L, Timmers M, Streffer JR. Allosteric alpha-7 nicotinic receptor modulation and P50 sensory gating in schizophrenia: a proof-of-mechanism study. Neuropharmacology. 2013 Jan;64:197-204. doi: 10.1016/j.neuropharm.2012.06.040. Epub 2012 Jul 2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	JNJ-39393406	Small molecule	10 mg	Oral
Subject	JNJ-39393406	Small molecule	30 mg	Oral
Subject	JNJ-39393406	Small molecule	50 mg	Oral
Subject	JNJ-39393406	Small molecule	100 mg	Oral
Subject	JNJ-39393406	Small molecule	200 mg	Oral

Indications